Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-MV in Antiviral-Resistant CMV, BKV, or EBV Infection Following Anticancer Therapy or Allo-HSCT
NCT07670468Phase 2Recruiting
- Sponsor
- LucasBio
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of LB-DTK-MV in cytomegalovirus infection (CMV), BK virus infection, Epstein-Barr virus infection, sponsored by LucasBio. Started Dec 2025; status: recruiting.
02
Drugs
LB-DTK-MV
03
Conditions
cytomegalovirus infection (CMV)BK virus infectionEpstein-Barr virus infection
Beyond the preview
Go deeper on NCT07670468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670468.